This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sigma-Aldrich's CEO Hosts 2012 Business Review Conference (Transcript)

What I'm going to do is I'm going to give you a quick overview of Sigma-Aldrich, I going to talk about some of the markets and the trends and how it impacts us as a company. And of course, I'm going to talk to you about how we are positioning the company for the future, our strategic priorities and where you can expect this company is going in the next several years.

So with that -- our vision remains the same. It's simple, it's to enable science to improve the quality of life. And that it has an enduring purpose that has endured for many years. And if you'd look at our mission statement, it's to be the trusted and preeminent global provider to both the research laboratory, as well as targeted commercial markets. So we are playing, and we'll talk a lot about that today, in the lab space but also in targeted commercial markets and adjacencies.

Just some facts about the company. We have a global franchise that is extremely strong. And that strength really is in the diversity of what this company does. We have diversity in the products that we offer, the services that we offer, we have diversity in the geographic segments that we play in and we have diversity in the end market. So as you see, for most of you who've been following us, you can see that from a geographic standpoint, very quickly the feast of our business in the emerging markets that we refer to usually as APLA, as in Asia-Pacific and Latin America, has been growing. And that's about 23% of the business. And Eric Green, who runs that part of the business is going to, kind of, talk to you more about that in the end this morning, about very exciting things happening. If you look at the end market, again about 1/3 of our business is tied to pharma and biotech, about 1/3 is tied to the Industrial segment and close to a little less than 1/3 of our 25% is tied to academia and government institutions.

4 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs